{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:22:12Z","timestamp":1791235332066,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Antiphospholipid syndrome (APS) is an autoimmune disorder in which autoantibodies cause clinical effects of vascular thrombosis and pregnancy morbidity. The only evidence-based treatments are anticoagulant medications such as warfarin and heparin. These medications have a number of disadvantages, notably risk of haemorrhage. Therefore, there is a pressing need to develop new, more focused treatments that target the actual pathogenic disease process in APS. The pathogenic antibodies exert their effects by interacting with phospholipid-binding proteins, of which the most important is beta-2-glycoprotein I. This protein has five domains, of which the N-terminal Domain I (DI) is the main site for binding of pathogenic autoantibodies. We previously demonstrated bacterial expression of human DI and showed that this product could inhibit the ability of IgG from patients with APS (APS-IgG) to promote thrombosis in a mouse model. Since DI is a small 7kDa protein, its serum half-life would be too short to be therapeutically useful. We therefore used site-specific chemical addition of polyethylene glycol (PEG) to produce a larger variant of DI (PEG-DI) and showed that PEG-DI was equally effective as the non-PEGylated DI in inhibiting thrombosis caused by passive transfer of APS-IgG in mice. In this paper, we have used a mouse model that reflects human APS much more closely than the passive transfer of APS-IgG. In this model, the mice are immunized with human beta-2-glycoprotein I and develop endogenous anti-beta-2-glycoprotein I antibodies. When submitted to a pinch stimulus at the femoral vein, these mice develop clots. Our results show that PEG-DI inhibits production of thromboses in this model and also reduces expression of tissue factor in the aortas of the mice. No toxicity was seen in mice that received PEG-DI. Therefore, these results provide further evidence supporting possible efficacy of PEG-DI as a potential treatment for APS.<\/jats:p>","DOI":"10.3389\/fimmu.2022.842923","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T06:01:27Z","timestamp":1649656887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Rohan","family":"Willis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C. R.","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Pericleous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio B.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Schleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zurina","family":"Romay-Penabad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian P.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40901","article-title":"The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study","volume":"71","author":"Duarte-Garcia","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100610","DOI":"10.1016\/j.blre.2019.100610","article-title":"The Role of Beta-2-Glycoprotein I in Health and Disease Associating Structure With Function: More Than Just APS","volume":"39","author":"McDonnell","year":"2019","journal-title":"Blood Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/art.22306","article-title":"Binding of Antiphospholipid Antibodies to Discontinuous Epitopes on Domain I of Human Beta(2)-Glycoprotein I: Mutation Studies Including Residues R39 to R43","volume":"56","author":"Ioannou","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.12.7097","article-title":"Use of Single Point Mutations in Domain I of Beta 2-Glycoprotein I to Determine Fine Antigenic Specificity of Antiphospholipid Autoantibodies","volume":"169","author":"Iverson","year":"2002","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-001206","article-title":"Current Concepts on the Pathogenesis of the Antiphospholipid Syndrome","volume":"109","author":"Giannakopoulos","year":"2007","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.9.1050","article-title":"Management of Antiphospholipid Antibody Syndrome: A Systematic Review","volume":"295","author":"Lim","year":"2006","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310395803","article-title":"Evidence-Based Recommendations for the Prevention and Long-Term Management of Thrombosis in Antiphospholipid Antibody-Positive Patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies","volume":"20","author":"Ruiz-Irastorza","year":"2011","journal-title":"Lupus"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR Recommendations for the Management of Antiphospholipid Syndrome in Adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban Versus Warfarin to Treat Patients With Thrombotic Antiphospholipid Syndrome, With or Without Systemic Lupus Erythematosus (RAPS): A Randomised, Controlled, Open-Label, Phase 2\/3, non-Inferiority Trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs Warfarin in High-Risk Patients With Antiphospholipid Syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Internal Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.10.014","article-title":"Efficacy of Aspirin for the Primary Prevention of Thrombosis in Patients With Antiphospholipid Antibodies: An International and Collaborative Meta-Analysis","volume":"13","author":"Arnaud","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1472-6750-6-8","article-title":"A Novel Expression System of Domain I of Human Beta2 Glycoprotein I in Escherichia Coli","volume":"6","author":"Ioannou","year":"2006","journal-title":"BMC Biotechnol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03316.x","article-title":"In Vivo Inhibition of Antiphospholipid Antibody-Induced Pathogenicity Utilizing the Antigenic Target Peptide Domain I of Beta2-Glycoprotein I: Proof of Concept","volume":"7","author":"Ioannou","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket278","article-title":"PEGylated Drugs in Rheumatology\u2013Why Develop Them and do They Work","volume":"53","author":"McDonnell","year":"2014","journal-title":"Rheumatol (Oxford)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1517\/14728210902907847","article-title":"Emerging PEGylated Drugs","volume":"14","author":"Kang","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2174\/1381612023393242","article-title":"Structure, Biology, and Therapeutic Implications of Pegylated Interferon Alpha-2b","volume":"8","author":"Youngster","year":"2002","journal-title":"Curr Pharm Des"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio786","article-title":"Site-Specific PEGylation of Native Disulfide Bonds in Therapeutic Proteins","volume":"2","author":"Shaunak","year":"2006","journal-title":"Nat Chem Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.04.011","article-title":"Pegloticase Treatment of Chronic Refractory Gout: Update on Efficacy and Safety","volume":"50","author":"Schlesinger","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02413","article-title":"PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome","volume":"9","author":"McDonnell","year":"2018","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.7.1746","article-title":"Thrombogenic Properties of Murine Anti-Cardiolipin Antibodies Induced by Beta 2 Glycoprotein 1 and Human Immunoglobulin G Antiphospholipid Antibodies","volume":"94","author":"Pierangeli","year":"1996","journal-title":"Circulation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12896-015-0222-0","article-title":"Development of a High Yield Expression and Purification System for Domain I of Beta-2-Glycoprotein I for the Treatment of APS","volume":"15","author":"McDonnell","year":"2015","journal-title":"BMC Biotechnol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.40195","article-title":"Major Histocompatibility Complex Class II Alleles Influence Induction of Pathogenic Antiphospholipid Antibodies in a Mouse Model of Thrombosis","volume":"69","author":"Papalardo","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical Course of High-Risk Patients Diagnosed With Antiphospholipid Syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemostasis"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.155.3.1629","article-title":"Epitope Specificity of Monoclonal Anti-Beta 2-Glycoprotein I Antibodies Derived From Patients With the Antiphospholipid Syndrome","volume":"155","author":"Wang","year":"1995","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1191\/0961203306lu2315oa","article-title":"A Peptide That Mimics the Vth Region of Beta-2-Glycoprotein I Reverses Antiphospholipid-Mediated Thrombosis in Mice","volume":"15","author":"Ostertag","year":"2006","journal-title":"Lupus"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2011.11.009","article-title":"Anti-Phospholipid Induced Murine Fetal Loss: Novel Protective Effect of a Peptide Targeting the Beta2 Glycoprotein I Phospholipid-Binding Site. Implications for Human Fetal Loss","volume":"38","author":"de la Torre","year":"2012","journal-title":"J Autoimmun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e15345","DOI":"10.1371\/journal.pone.0015345","article-title":"A Novel Dimeric Inhibitor Targeting Beta2GPI in Beta2GPI\/antibody Complexes Implicated in Antiphospholipid Syndrome","volume":"5","author":"Kolyada","year":"2010","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-520882","article-title":"Inhibition of Thrombotic Properties of Persistent Autoimmune Anti-Beta2gpi Antibodies in the Mouse Model of Antiphospholipid Syndrome","volume":"123","author":"Kolyada","year":"2014","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13185","article-title":"An A1-A1 Mutant With Improved Binding and Inhibition of Beta2gpi\/Antibody Complexes in Antiphospholipid Syndrome","volume":"282","author":"Kolyada","year":"2015","journal-title":"FEBS J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13314","article-title":"Soluble Analog of ApoER2 Targeting Beta2-Glycoprotein I in Immune Complexes Counteracts Hypertension in Lupus-Prone Mice With Spontaneous Antiphospholipid Syndrome","volume":"14","author":"Kolyada","year":"2016","journal-title":"J Thromb Haemost"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.842923\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T09:26:44Z","timestamp":1675243604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.842923\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2022.842923"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.842923","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"article-number":"842923"}}